The pharmacology of bosentan

Bibliography

• YANAGISAWA MH, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vas- cular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• INOUE A, YANAGISAWA M, KIMURA S et al: The human endothelin family - three structurally and pharmaco-logically distinct isopeptides predicted by three sepa-rate genes. Proc. Natl. Acad. ScL USA (1989) 86:2863–2867.
   PubMed Web of Science ®Google Scholar
• MCMILLEN MA, SUMPIO BE: Endothelins: polyfunc-tional cytokines. J. Am. Coll. Surg. (1995) 180:621–637.
   PubMed Web of Science ®Google Scholar
• RUBANYI GM, POLOKOFF MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. (1994) 46:328–415.
   Web of Science ®Google Scholar
• GOTO K, HAMA H, KASUYA Y: Molecular pharmacology and pathophysiological significance of endothelin. Jpn. J. Pharmacol. (1996) 72:261–290.
   PubMedGoogle Scholar
• SAKURAI T, YANAGISAWA M, TAKUWA Y et al.: Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature (1990) 348:732–735.
   PubMed Web of Science ®Google Scholar
• ARAI H, HORI S, ARAMORI I, OHKUBO H, NAKANISHI S: Cloning and expression of a cDNA encoding an endo-thelin receptor. Nature (1990) 348:730–732.
   PubMed Web of Science ®Google Scholar
• KARNE S, JAYAWICKREME CK, LERNER MR: Cloning and characterization of an endothelin-3 specific receptor (ETc receptor) from Xenopus laevis dermal melano-phores. J. Biol. Chem. (1993) 268:19126–19133.
   PubMed Web of Science ®Google Scholar
• OHLSTEIN EH, DOUGLAS SA: Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug De-velop. Res. (1993) 29:108–128.
   Web of Science ®Google Scholar
• OGAWA Y, NAKAO K, ARAI H et al: Molecular cloning of a non-isopeptide-selective human endothelin recep-tor. Biochem. Biophys. Res. Commun. (1991) 178:248–255.
   PubMed Web of Science ®Google Scholar
• WARNER TD, MITCHELL JA, DENUCCI G, VANE JR: Endothelin-1 and endothelin-3 release EDRF from iso-lated perfused arterial vessels of rat and rabbit. J. Car-diovasc. Pharmacol. (1989) 13:S85–S88.
   PubMed Web of Science ®Google Scholar
• DE NUCCI G, THOMAS R, D'ORLEANS-JUSTE D et al: Pres-sor effects of circulating endothelin are limited by its removal in the pulmonay circulation and by the re-lease of prostacyclin and endothelium-derived relax-ing factor. Proc. Natl. Acad. Sci. USA (1988) 85:9797–9800.
   PubMed Web of Science ®Google Scholar
• SUMNER MJ, CANNON TR, MUNDIN JM, WHITE DG, WATTS IS: Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br. J. Pharmacol (1992) 107:858–860.
   PubMed Web of Science ®Google Scholar
• SIMONSON MS, DUNN MJ: Endothelin peptides and thekidney. Annu. Rev. Physiol. (1993) 55:249–265.
   PubMed Web of Science ®Google Scholar
• LA DOUCEUR DM, FLYNN MA, KEISER JA, REYNOLDS E,HALEEN SJ: ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction. Biochem. Biophys. Res. Commun. (1993) 196:209–215.
   PubMed Web of Science ®Google Scholar
• SEO B, OEMAR BS, SIEBENMANN R, VON SEGESSER L,LOSCHER TF: Both ETA and ETB receptors mediate con-traction to endothelin-1 in human blood vessels. Cir-culation (1994) 89:1203–1208.
   PubMed Web of Science ®Google Scholar
• FUKURODA T, FUJIKAWA T, OZAKI S et al: Clearance of circulating endothelin-1 by ETB receptors in rats. Bio-chem. Biophys. Res. Commun. (1994) 199:1461–1465.
   PubMed Web of Science ®Google Scholar
• HEMSEN A, MODIN A, WANECEK M, MALMSTROM RE, WEITZBERG E: Effects of Ro 47-0203 and PD155080 on the plasma kinetics, receptor binding and vascular ef-fects of endothelin in the pig. Eur. J. Pharmacol (1996) 318:369–376.
   PubMed Web of Science ®Google Scholar
• LOSCHER TF, SEO B-G, BOHLER FR: Controversy on en-dothelin in hypertension: the potential role of endo-thelin in hypertension. Hypertension (1993) 21: 752–757.
   PubMed Web of Science ®Google Scholar
• WEITZBERG E, LUNDBERG JM, RUDEHILL A: Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ. Shock (1991) 33:222–227.
   PubMedGoogle Scholar
• LERMAN A, EDWARDS BS, HALLETT JW et al: Circulatingand tissue endothelin immunoreactivity in advanced atherosclerosis. New Engl. J. Med. (1991) 325:997–1001.
   PubMed Web of Science ®Google Scholar
• STEWART DJ, KUBAG G, COSTELLO KB, CERNACEK P: In-creased plasma endothelin-1 in early hours of acute myocardial infarction. J. Am. Coll. Cardiol. (1991) 18:38–43.
   PubMed Web of Science ®Google Scholar
• MCMURRAY JJ, RAY SG, ABDULLAH I, DARGIE HJ, MOR-TON JJ: Plasma endothelin in chronic heart failure. Cir-culation (1992) 85:1374–1379.
   PubMed Web of Science ®Google Scholar
• KOYAMA H, TABATA T, NISHZAWA Y et al: Plasma endo-thelin levels in patients with uraemia. Lancet (1989) 1:991–992.
   PubMed Web of Science ®Google Scholar
• SPRINGALL DR, HOWARTH PH, COUNIHAN H et al.: En-dothelin immunoreactivity of airway epithelium in asthmatic patients. Lancet (1991) 337:697–701.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, BREU V, BURRI K et al.: Pathophysiological role of endothelin revealed by the first orally active en-dothelin receptor antagonist. Nature (1993) 365:759–761.
   PubMed Web of Science ®Google Scholar
• NEIDHART W, BREU V, BUR D et al.: The discovery of nonpeptide endothelin receptor antagonists. Progres-sion towards bosentan. Chimia (1996) 50:519–524.
   Google Scholar
• CLOZEL M, BREU V, GRAY GA et al.: Pharmacological characterization of bosentan, a new potent orally ac-tive nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. (1994) 270:228–235.
   PubMed Web of Science ®Google Scholar
• DASHWOOD MR, TIMM M, MUDDLE JR et al.: [311]Bosen-tan binding to human coronary artery: functional cor-relates. J. Cardiovasc. Pharmacol. (1995) 26:S376–379.
   PubMed Web of Science ®Google Scholar
• TSCHUDI MR, LIISCHER TF: Characterization of contrac-tile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem. Biophys. Res. Com-mun. (1994) 204:685–690.
   PubMed Web of Science ®Google Scholar
• GATER PR, WASSERMAN MA, RENZETTI LM: Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig tra-chea. Eur. J. Pharmacol. (1996) 304:123–128.
   PubMed Web of Science ®Google Scholar
• VENIANT M, CLOZEL JP, HESS P, CLOZEL M: Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. Life ScL (1994) 55:445–454.
   PubMed Web of Science ®Google Scholar
• PHILLIPS PA, RISVANIS J, ALDRED K, BURRELL LM, BAR-THOLOMEUSZ B: Differential effects of a novel non-peptide endothelin receptor antagonist (bosentan) in rat liver and vasculature. Clin. ScL (1995) 89:575–579.
   PubMed Web of Science ®Google Scholar
• WANG QD, LI XS, LUNDBERG JM, PERNOW J: Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc. Res. (1995) 29:805–812.
   PubMed Web of Science ®Google Scholar
• WHITE LR, BAKKEN IJ, SJAAVAAG I et al.: Vasoactivity mediated by endothelin ETA and ETB receptors in iso-lated porcine ophthalmic artery. Acta Physiol. Scand. (1996) 157:245–252.
   PubMedGoogle Scholar
• GARDINER SM, KEMP PA, MARCH JE, BENNETT T: Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor an-tagonist, on regional haemodynamic responses to en-dothelins in conscious rats. Br. J. Pharmacol. (1994) 112:823–830.
   PubMed Web of Science ®Google Scholar
• LAWRENCE E, BRAIN SD: Effect of BQ-123 and Ro 47-0203 (bosentan) on endothelin-induced vasoconstric-tion in the rat skin. Eur. J. Pharmacol (1994) 260:103–106.
   PubMed Web of Science ®Google Scholar
• HOLM P, LISKA J, CLOZEL M, FRANCO-CERECEDA A: Theendothelin antagonist bosentan: hemodynamic ef-fects during normoxia and hypoxic pulmonary hyper-tension in pigs. J. Thorac. Cardiovasc. Surg. (1996) 112:890–897.
   PubMed Web of Science ®Google Scholar
• WEBER C, SCHMITT R, BIRNBOECK H et al.: Pharmacoki-netics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human sub-jects. Clin. Pharmacol. Ther. (1996) 60:124–137.
   PubMed Web of Science ®Google Scholar
• TEERLINK JR, CARTEAUX JP, SPRECHER U et al.: Role of endogenous endothelin in normal hemodynamic status of anaesthetised dogs. Am. J. Physiol. (1995) 268:H432–440.
   PubMed Web of Science ®Google Scholar
• SHIMOYAMA H, SABBAH HN, BORZAK S et al: Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation (1996) 94:779–784.
   PubMed Web of Science ®Google Scholar
• BARTHOLOMEUSZ B, HARDY KJ, NELSON AS, PHILLIPSPA: Bosentan ameliorates cyclosporin A-induced hy-pertension in rats and primates. Hypertension (1996) 27:1341–1345.
   PubMed Web of Science ®Google Scholar
• LI XS, WANG QD, PERNOW J: Beneficial effects of the en-dothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfu-sion in the rat. Eur. J. Pharmacol. (1995) 283:161–168.
   PubMed Web of Science ®Google Scholar
• GURBANOV K, RUBINSTEIN I, HOFFMAN A et al.: Bosen-tan improves renal regional blood flow in rats with ex-perimental congestive heart failure. Eur. J. Pharmacol (1996) 310:193–196.
   PubMed Web of Science ®Google Scholar
• HOCHER B, ROHMEISS P, DIEKMANN F et al.: Distribu-tion of endothelin receptor subtypes in the rat kidney. Renal and haemodynamic effects of the mixed (A/B) endothelin receptor antagonist bosentan. Eur. J. Clin. Chem. Clin. Biochem. (1995) 33:463–472.
   PubMedGoogle Scholar
• MATSUMARU K, KASHIMURA H, HASSAN M et al.: Bosen-tan, a novel synthetic mixed-type endothelin receptor antagonist, attenuates acute gastric mucosal lesions in-duced by indomethacin and HC1 in the rat: role of en-dogenous endothelin-1. J. Gastroenterol. (1997) 32:164–170.
   PubMed Web of Science ®Google Scholar
• WEITZBERG E, HEMSEN A, RUDEHILL A et al: Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in por-cine endotoxin shock. Br. J. Pharmacol. (1996) 118:617–626.
   PubMed Web of Science ®Google Scholar
• LI JS, LARIVIERE R, SCHIFFRIN EL: Effect of a nonselective endothelin antagonist on vascular remodeling in de-oxycorticosterone acetate-salt hypertensive rats. Evi-dence for a role of endothelin in vascular hypertrophy. Hypertension (1994) 24:183–188.
   Google Scholar
• DONCKIER J, STOLERU L, HAYASHIDA W et al.: Role of endogenous endothelin-1 in experimental renal hy-pertension in dogs. Circulation (1995) 92:106–113.
   PubMed Web of Science ®Google Scholar
• BREU V, HASHIDO K, BROGER C et al.: Separable bind-ing sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors. Eur. j Biochem. (1995) 231:266–270.
   PubMedGoogle Scholar
• SAKAMOTO A, YANAGISAWA M, SAWAMURA T et al: Dis-tinct subdomains of human endothelin receptors de-termine their selectivity to endothelinA-selective antagonists and endothelinB-selective agonists. J. Biol. Chem. (1993) 268:8547–8553.
   PubMed Web of Science ®Google Scholar
• WEBB ML, PATEL PS, ROSE PM et al: Mutational analysisof the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity. Biochemistry (1996) 35:2548–2556.
   PubMed Web of Science ®Google Scholar
• ADACHI M, FURUICHI Y, MIYAMOTO C: Identification ofa region of the human endothelin ETA receptor re-quired for interaction with bosentan. Eur. J. Pharmacol. (1994) 269:225–234.
   PubMed Web of Science ®Google Scholar
• WADA K, HASHIDO K, TERASHIMA H et al: Ligand bind-ing domain of the human endothelin-B subtype recep-tor. Protein Express. Puri": (1995) 6:228–236.
   Google Scholar
• TAKANASHI M, ENDOH M: Characterization of positive inotropic effect of endothelin on mammalian ven-tricular myocardium. Am. J. Physic)]. (1991) 261:H611–H619.
   Web of Science ®Google Scholar
• HARADA M, ITOH H, NAKAGAWA 0 et al.: Significanceof ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation (1997) 96:3737–3744.
   Google Scholar
• HIRATA Y, TAKAGI Y, FUKUDA Y, MARUMO F: Endothe-lin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis (1989) 78:225–228.
   PubMed Web of Science ®Google Scholar
• MORBIDELLI L, ORLANDO C, MAGGI CA, LEDDA F, ZICHE M: Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB recep-tors. Am. J. Physic)]. (1995) 269:H686–695.
   PubMed Web of Science ®Google Scholar
• TAKUWA N, TAKUWA Y, YANAGISAWA M, YAMASHITAK, MASAKI T: A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J. Biol. Chem. (1989) 264:7856–7861 .
   PubMed Web of Science ®Google Scholar
• CODY RJ, HAAS GJ, BINKLEY PF, CAPERS Q, KELLY R:Plasma endothelin correlates with the extent of pul-monary hypertension in patients with chronic con-gestive heart failure. Circulation (1992) 85:504–509.
   PubMed Web of Science ®Google Scholar
• LIU J, CHEN R, CASLEY DJ, NAYLER WG: Ischaemia andreperfusion increases 125I-labeled endothelin-1 bind-ing in rat cardiac membranes. Am. J. Physiol. (1990) 258:H829–835.
   PubMed Web of Science ®Google Scholar
• TEERLINK JR, LOFFLER BM, HESS P et al: Role of endothe-lin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the en-dothelin receptor antagonist Ro 47-0203 (bosentan). Circulation (1994) 90:2510–2518.
   Google Scholar
• WANG QD, HEMSEN A, LI XS et al.: Local overflow and enhanced tissue content of endothelin following myo-cardial ischaemia and reperfusion in the pig: modula-tion by L-arginine. Cardiovasc. Res. (1995) 29:44–49.
   PubMed Web of Science ®Google Scholar
• TONNESSEN T, NAESS PA, KIRKEBOEN KA et al.: Endo-thelin is released from the porcine coronary circula-tion after short-term ischaemia. J. Cardiovasc. Pharmacol. (1993) 22:S313–S316.
   PubMed Web of Science ®Google Scholar
• CAVERO PG, MILLER WL, HEUBLEIN DM, MARGULIES KB, BURNETT JCJ: Endothelin in experimental congestive heart failure in the anesthetized dog. Am. J. Physic)]. (1990) 259:F312–F317.
   Web of Science ®Google Scholar
• VELASCO CE, TURNER M, INAGAMI T et al: Reperfusion enhances the local release of endothelin after regional myocardial ischaemia. Am. Heart J. (1994) 128:441–451.
   PubMed Web of Science ®Google Scholar
• KUSUMOTO K, AWANE Y, FUJIWARA S, WATANABE T: Role of endogenous endothelin in extension of rabbit myocardial infarction. J. Cardiovasc. Pharmacol (1993) 22:S339–S342.
   PubMed Web of Science ®Google Scholar
• PACHER R, STANEK B, HULSMANN M et al: Prognosticimpact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol. (1996) 27:633–641.
   PubMed Web of Science ®Google Scholar
• KRUM H, GOLDSMITH R, WILSHIRE-CLEMENT M, MILLER M, PACKER M: Role of endothelin in the exercise intol-erance of chronic heart failure. Am. J. Cardiol (1995) 75:1282–1283.
   PubMed Web of Science ®Google Scholar
• SHAH AM, LEWIS MJ, HENDERSON AH: Inotropic effects of endothelin in ferret ventricular myocardium. Eur. J. Pharmacol. (1989) 163:365–367.
   PubMed Web of Science ®Google Scholar
• TIPPINS JR, ANTONIW JW, MASERI A: Endothelin-1 is a potent constrictor in conductive and resistive coro-nary arteries. J. Cardiovasc. Pharmacol. (1989) 13:S177–179.
   PubMed Web of Science ®Google Scholar
• TEERLINK JR, GOLDHABER SZ, PFEFFER MA: An over-view of contemporary aetiologies of congestive heart failure. Am. Heart J. (1991) 121:1852–1853.
   PubMed Web of Science ®Google Scholar
• MULDER P, RICHARD V, DERUMEAUX G et al: Role of en-dogenous endothelin in chronic heart failure: effect of long- term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Cir-culation (1997) 96:1976–1982.
   PubMed Web of Science ®Google Scholar
• FRACCAROLLO D, HU K, GALUPPO P, GAUDRON P, ERTL G: Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ven-tricular remodeling. Circulation (1997) 96:3963–3973.
   PubMed Web of Science ®Google Scholar
• KADDOURA S, FIRTH JD, BOHELER KR, SUGDEN PH, POOLE-WILSON PA: Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circula-tion (1996) 93:2068–2079.
   Google Scholar
• KAASJAGER KA, SHAW S, KOOMANS HA, RABELINK TJ: Role of endothelin receptor subtypes in the systemic © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7) and renal responses to endothelin-1 in humans. J. Am. Soc. Nephrol. (1997) 8:32–39.
   Google Scholar
• SAKAI S, MIYAUCHI T, KOBAYASHI M et al: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature (1996) 384:353–355.
   PubMed Web of Science ®Google Scholar
• DAGASSAN PH, BREU V, CLOZEL M et al: Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J. Cardiovasc. Pharmacol. (1996) 27:147–153.
   PubMed Web of Science ®Google Scholar
• CANNAN CR, BURNETT JC, LERMAN A: Enhanced coro-nary vasoconstriction to endothelin-B-receptor activa-tion in experimental congestive heart failure. Circulation (1996) 93:646–651.
   PubMed Web of Science ®Google Scholar
• LOVE MP, HAYNES WG, GRAY GA, WEBB DJ, MCMURRAY JJ: Vasodilator effects of endothelin-converting en-zyme inhibition and endothelin ETA receptor block-ade in chronic heart failure patients treated with ACE inhibitors. Circulation (1996) 94:2131–2137.
   PubMed Web of Science ®Google Scholar
• GUARDA E, KATWA LC, MYERS PR, TYAGI SC, WEBER KT:Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc. Res. (1993) 27:2130–2134.
   PubMed Web of Science ®Google Scholar
• BELLONI AS, PACHECO YG, MARKOWSKA A et al: Distri-bution and functional significance of the endothelin receptor subtypes in the rat adrenal gland. Cell Tissue Res. (1997) 288:345–352.
   PubMed Web of Science ®Google Scholar
• WANG QD, LI XS, PERNOW J: The nonpeptide endothe-lin receptor antagonist bosentan enhances myocar-dial recovery and endothelial function during reperfusion of the ischemic rat heart. J. Cardiovasc. Pharmacol. (1995) 26:S445–447.
   PubMed Web of Science ®Google Scholar
• FILEP JG, FOURNIER A, FOLDES-FILEP E: Effects of the ETA/ETB receptor antagonist, bosentan on endothelin-1- induced myocardial ischaemia and oe-dema in the rat. Br. J. Pharmacol. (1995) 116:1745–1750.
   PubMed Web of Science ®Google Scholar
• FILEP JG, FOURNIER A, FOLDES-FILEP E: Endothelin-1-induced myocardial ischaemia and oedema in the rat: involvement of the ETA receptor, platelet-activating factor and thromboxane A2. Br. J. Pharmacol. (1994) 112:963–971.
   PubMed Web of Science ®Google Scholar
• GAVIN JB, HUMPHREY SM, HERDSON PB: The no-reflow phenomenon in ischaemic myocardium. Int. Rev. Exp. Pathol. (1983) 25:361.
   PubMedGoogle Scholar
• DAGASSAN PH, BREU V, CLOZEL M, CLOZEL JP: Role of endothelin during reperfusion after ischaemia in iso-lated perfused rat heart. J. Cardiovasc. Pharmacol (1994) 24:867–874.
   PubMed Web of Science ®Google Scholar
• RICHARD V, KAEFFER N, HOGIE M, TRON C, BLANC T,THUILLEZ C: Role of endogenous endothelin in myo-cardial and coronary endothelial injury after ischae-mia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist. Br. J. Pharmacol (1994) 113:869–876.
   PubMed Web of Science ®Google Scholar
• ISKIT AB, GUC MO: Thimerosal attenuates ischaemia-reperfusion arrhythmias in rats: no modification by anti-ischaemic agent trimetazidine or endothelin re-ceptor antagonist bosentan. Pharmacol. Res. (1996) 34:17–23.
   PubMed Web of Science ®Google Scholar
• HEATH D, SMITH P, GOSNEY J et al.: The pathology of the early and late stages of primary-pulmonary hyper-tension. Br. Heart J. (1987) 58:204–213.
   PubMedGoogle Scholar
• GIAID A, YANAGISAWA M, LANGLEBEN D et al.: Expres-sion of endothelin-1 in the lungs of patients with pul-monary hypertension. New EngL J. Med. (1993) 328:1732–1739.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA S, MIYAUCHI T, UENO H et al.: Influence ofpulmonary blood pressure and flow on endothelin-1 production in humans. J. Cardiovasc. Pharmacol. (1995) 26:429–433.
   Web of Science ®Google Scholar
• EDDAHIBI S, RAFFESTIN B, CLOZEL M, LEVAME M, AD-NOT S: Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hy-poxic rats. Am. J. Physiol. (1995) 268:H828–835.
   PubMed Web of Science ®Google Scholar
• HESS P, CLOZEL M, CLOZEL JP: Telemetry monitoring of pulmonary arterial pressure in freely moving rats. J. Appl. Physiol. (1996) 81:1027–1032.
   PubMed Web of Science ®Google Scholar
• HILL NS, WARBURTON RR, PIETRAS L, KLINGER JR: Non-specific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J. AppL Physic]. (1997) 83:1209–1215.
   PubMed Web of Science ®Google Scholar
• CHEN SJ, CHEN YF, MENG QC et al.: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physic]. (1995) 79:2122–2131.
   PubMed Web of Science ®Google Scholar
• HAY DWP, HENRY PJ, GOLDIE RG: Endothelin and therespiratory system. Trends Pharmacol. ScL (1993) 14:29–32.
   PubMed Web of Science ®Google Scholar
• FILEP JG, FOURNIER A, FOLDES-FILEP E: Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors. Br J. Pharmacol. (1995) 115:227–236.
   PubMed Web of Science ®Google Scholar
• PARK SH, SALEH D, GIAID A, MICHEL RP: Increasedendothelin-1 in bleomycin-induced pulmonary fibro-sis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. (1997) 156:600–608.
   PubMed Web of Science ®Google Scholar
• ABRAHAM DJ, VANCHEESWARAN R, DASHWOOD MR et al.: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pa-thol. (1997) 151:831–841.
   PubMed Web of Science ®Google Scholar
• GOLDIE RG, HENRY PJ, KNOTT PG et al.: Endothelin-1 receptor density, distribution and function in human isolated asthmatic airways. Am. J. Respir. Crit. Care Med. (1995) 152:1653–1659.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, BARNES PJ, KAWIKOVA I et al.: Contrac-tion of human airway smooth muscle by endothelin-1 and IRL 1620: effect of bosentan. Eur. J. Pharmacol. (1997) 324:219–222.
   PubMed Web of Science ®Google Scholar
• LAL H, WOODWARD B, WILLIAMS KI: Actions of endo-thelins and sarafotoxin 6c in the rat isolated perfused lung. Br. J. Pharmacol (1995) 115:653–659.
   PubMed Web of Science ®Google Scholar
• NAMBI P, PULLEN M, SPIELMAN W: Species differences in the binding characteristics of [ 125IIIRL-1620, a © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7) potent agonist specific for endothelin-B receptors. J. Pharmacol. Exp. Ther. (1994) 268:202–207.
   Google Scholar
• FINSNES F, SKJONSBERG OH, TONNESSEN T et al: Endo-thelin production and effects of endothelin antago-nism during experimental airway inflammation. Am. J. Respir. Grit. Care Med. (1997) 155:1404–1412.
   PubMed Web of Science ®Google Scholar
• ANDERSSON SE, HEMSEN A, LUNDBERG JM: The effect of endothelin receptor blockade on the development of the sephadex-induced inflammation in the rat lung. Acta Physiol. Scand. (1996) 158:189–193.
   PubMedGoogle Scholar
• SCHIFFRIN EL, THIBAULT G: Plasma endothelin in hu-man essential hypertension. Am. J. Hypertens. (1991) 4:303–308.
   PubMed Web of Science ®Google Scholar
• KOHNO M, YASUNARI K, MURAKAWA KI et al: Plasma immunoreactive endothelin in essential hyperten-sion. Am. J. Med. (1990) 88:614–618.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, SVENTEK P, LI JS, TURGEON A, REUDEL-HUBER T: Antihypertensive effect of an endothelin re-ceptor antagonist in DOCA-salt spontaneously hypertensive rats. Br. J. Pharmacol. (1995) 115:1377–1381 .
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, LARIVIERE R, LI JS, SVENTEK P, TOUYZ RM: Deoxycorticosterone acetate plus salt induce overex-pression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hy-pertension (1995) 25 (part 2) :769–773.
   Google Scholar
• KARAM H, HEUDES D, HESS P et al: Respective role of humoral factors and blood pressure in cardiac remod-eling of DOCA hypertensive rats. Cardiovasc. Res. (1996) 31:287–295.
   PubMed Web of Science ®Google Scholar
• ITO H, HIRATA Y, HIROE M et al.: Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyo-cytes. Circ. Res. (1991) 69:209–215.
   PubMed Web of Science ®Google Scholar
• JANAKIDEVI K, FISHER MA, DEL VECCHIO PJ et al.: Endo-thelin 1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle. Am. J. Physiol. (1992) 263:C1295–C1301.
   Google Scholar
• HAHN AW, RESINK TJ, KERN F, BUHLER FR: Peptide vaso-constrictors, vessel structure, and vascular smooth muscle cell proliferation. J. Cardiovasc. Pharmacol. (1993) 22:S37–S43.
   PubMed Web of Science ®Google Scholar
• LI JS, SCHURCH W, SCHIFFRIN EL: Renal and vascular ef-fects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am. J. Hypertens. (1996) 9:803–811.
   PubMed Web of Science ®Google Scholar
• LARIVIERE R, SVENTEK P, THIBAULT G, SCHIFFRIN EL: Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA/ETB endothelin receptor antagonist bosentan. Can. J. Physic]. Pharmacol. (1995) 73:390–398.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, LARIVIERE R, LI JS, SVENTEK P: Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vas-cular structure. J. Vasc. Res. (1996) 33: 235–248.
   PubMed Web of Science ®Google Scholar
• LI JS, SCHIFFRIN EL: Chronic endothelin receptor an-tagonist treatment of young spontaneously hyperten-sive rats. J. Hypertens. (1995) 13:647–652.
   PubMed Web of Science ®Google Scholar
• LI JS, SCHIFFRIN EL: Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension (1995) 25:495–500.
   PubMed Web of Science ®Google Scholar
• LI JS, DENG LY, GROVE K, DESCHEPPER CF, SCHIFFRIN EL: Comparison of effect of endothelin antagonism and angiotensin- converting enzyme inhibition on blood pressure and vascular structure in spontane-ously hypertensive rats treated with N omega-nitro-L-arginine methyl ester. Correlation with topography of vascular endothelin-1 gene expression. Hypertension (1996) 28:188–195.
   Google Scholar
• KARAM H, HEUDES D, BRUNEVAL P et al.: Endothelin an-tagonism in end-organ damage of spontaneously hy-pertensive rats. Comparison with angiotensin -converting enzyme inhibition and calcium antago-nism. Hypertension (1996) 28: 379–385.
   Google Scholar
• DENG LY, SCHIFFRIN EL: Effects of endothelin-1 and va-sopressin on small arteries of spontaneously hyper-tensive rats. Am. J. Hypertens. (1992) 5: 817–822.
   PubMed Web of Science ®Google Scholar
• VERMA S, BHANOT S, MCNEILL JH: Effect of chronic en-dothelin blockade in hyperinsulinemic hypertensive rats. Am. J. Physiol. (1995) 269:H2017–2021.
   PubMed Web of Science ®Google Scholar
• HOCHER B, ROHMEISS P, ZART R et al.: Significance of endothelin receptor subtypes in the kidneys of spon-taneously hypertensive rats: renal and hemodynamic effects of endothelin receptor antagonists. J. Cardio-vasc. Pharmacol (1995) 26:S470–472.
   PubMed Web of Science ®Google Scholar
• HOCHER B, ROHMEISS P, ZART R et al.: Function and ex-pression of endothelin receptor subtypes in the kid-neys of spontaneously hypertensive rats. Cardiovasc. Res. (1996) 31:499–510.
   PubMed Web of Science ®Google Scholar
• SKOV K, FENGER-GRON J, MULVANY MJ: Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. Hypertension (1996) 28:464–471.
   PubMed Web of Science ®Google Scholar
• BOURIQUET N, DUPONT M, HERIZI A, MIMRAN A, CASEL-LAS D: Preglomerular sudanophilia in L-NAME hyper-tensive rats. Involvement of endothelin. Hypertension (1996) 27:382–391.
   PubMed Web of Science ®Google Scholar
• CHILLON JM, HEISTAD DD, BAUMBACH GL: Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension (1996) 27:794–798.
   PubMed Web of Science ®Google Scholar
• BREZIS M, EPSTEIN FH: Cellular mechanisms of acute ischemic injury in the kidney. Ann. Rev. Med. (1993) 44:27–37.
   PubMed Web of Science ®Google Scholar
• NORD EP: Renal actions of endothelin. Kidney Int. (1993) 44:451–463.
   PubMed Web of Science ®Google Scholar
• RABELINK TJ, KAASJAGER KAH, STROES ESG, KOOMANS HA: Endothelin in renal pathophysiology: from ex-perimental to therapeutic application. Kidney Int. (1996) 50:1827-1833. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7)
   Google Scholar
• KARAM H, BRUNEVAL P, CLOZEL JP et al.: Role of endo-thelin in acute renal failure due to rhabdomyolysis in rats. J. Pharmacol. Exp. Ther. (1995) 274:481–486.
   PubMed Web of Science ®Google Scholar
• KRAMER HJ, SCHWARTING K, BACKER A, MEYER-LEHNERT H: Renal endothelin system in obstructive jaundice: its role in impaired renal function of bile-duct ligated rats. Clin. ScL (1997) 92:579–585.
   PubMed Web of Science ®Google Scholar
• OLDROYD SD, HAYLOR JL, MORCOS SK: Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media. Radiology (1995) 196:661–665.
   PubMed Web of Science ®Google Scholar
• GOMEZ-GARRE D, LARGO R, LIU XH et al.: An orally ac-tive ETA/ETB receptor antagonist ameliorates protein-uria and glomerular lesions in rats with proliferative nephritis. Kidney Int. (1996) 50:962–972.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, ZOLA C, CORNA D et al: Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with rem-nant kidney. Am. J. Kidney Dis. (1996) 27:416–423.
   PubMed Web of Science ®Google Scholar
• HERRERO I, TORRAS J, RIERA M et al: Prevention of cold ischemia-reperfusion injury by an endothelin recep-tor antagonist in experimental renal transplantation. J. Am. Soc. Nephrol. (1997):657A (Abstr).
   Google Scholar
• KAWAMURA E, YAMANAKA N, OKAMOTO E, TOMODA F, FURUKAWA K: Response of plasma and tissue endothelin-1 to liver ischaemia and its implication in ischemia-reperfusion injury. Hepatology (1995) 21:1138–1143.
   PubMed Web of Science ®Google Scholar
• ASBERT M, GINES A, GINES P et al.: Circulating levels of endothelin in cirrhosis. Gastroenterology (1993) 104:1485–1491.
   PubMed Web of Science ®Google Scholar
• ROCKEY DC: Characterization of endothelin receptors mediating rat hepatic stellate cell contraction. Bio-chem. Biophys. Res. Commun. (1995) 207:725–731.
   PubMed Web of Science ®Google Scholar
• ROCKEY DC, CHUNG JJ: Endothelin antagonism in ex-perimental hepatic fibrosis. Implications for endothe-lin in the pathogenesis of wound healing. J. Clin. Invest. (1996) 98:1381–1388.
   Google Scholar
• HOUSSET C, ROCKEY DC, BISSEL DM: Endothelin recep-tors in rat liver: lipocytes as a contractile target for en-dothelin 1. Proc. Natl. Acad. ScL USA (1993) 90:9266–9270.
   PubMed Web of Science ®Google Scholar
• SPIEGEL HU, UHLMANN D, SCOMMOTAU S, GIERSCH B, SULKOWSKI U: Effect of the endothelin receptor an-tagonist bosentan on post-ischemic oxygen supply of the liver. J. Invest. Surg. (1996) 9:439–445.
   PubMed Web of Science ®Google Scholar
• SPIEGEL HU, SCOMMOTAU S, UHLMANN D, GIERSCH B: Effect of the endothelin receptor antagonist bosentan on post-ischemic liver microcirculation. Zentralbl. Chir. (1996) 121:788–793.
   PubMed Web of Science ®Google Scholar
• KOEPPEL TA, KRAUS T, THIES JC et al: Post-ischemic im-provement of hepatic microhemodynamics by a mixed ETA-, ETB-receptor antagonist (R0-47-0203). Transplant. Proc. (1997) 29:1365–1366.
   PubMed Web of Science ®Google Scholar
• PANNEN BH, BAUER M, ZHANG JX, ROBOTHAM JL, CLE-MENS MG: A time-dependent balance between endothelins and nitric oxide regulating portal resis-tance after endotoxin. Am. J. Physiol. (1996) 271:H1953–1961.
   PubMed Web of Science ®Google Scholar
• HOCHER B, ZART R, DIEKMANN F et al: Paracrine renal endothelin system in rats with liver cirrhosis. Br. J. Pharmacol. (1996) 118:220–227.
   PubMed Web of Science ®Google Scholar
• HOCHER B, ZART R, DIEKMANN F et al.: Protective ef-fects of the mixed endothelin receptor antagonist bo-sentan in rats with CCL4-induced liver injury. J. Cardiovasc. Pharmacol. (1995) 26:S130–131.
   PubMed Web of Science ®Google Scholar
• MICHIDA T, KAWANO S, MASUDA E et al.: Role of endothelin-1 in haemorrhagic shock-induced gastric mucosal injury in rats. Gastroenterology (1994) 106:988–993.
   PubMed Web of Science ®Google Scholar
• MURCH SH, BRAEGGER CP, SESSA WC, MACDONALD TT: High endothelin-1 immunoreactivity in Crohn's dis-ease and ulcerative colitis. Lancet (1992) 339:381–385.
   PubMed Web of Science ®Google Scholar
• LAZARATOS S, NAKAHARA A, GOTO K, FUKUTOMI H: Bo-sentan antagonises the effects of endothelin-1 on rat gastric blood flow and mucosal integrity. Life ScL (1995) 56:L195–200.
   Web of Science ®Google Scholar
• HOGABOAM CM, MULLER MJ, COLLINS SM, HUNT RH: An orally active non-selective endothelin receptor an-tagonist, bosentan, markedly reduces injury in a rat model of colitis. Eur. J. Pharmacol. (1996) 309:261–269.
   PubMed Web of Science ®Google Scholar
• ASANO T, IKEGAKI I, SUZUKI S, SHIBUYA M: Endothelin and the production of cerebral vasospasm in dogs. Bio-chem. Biophys. Res. Commun. (1989) 159:1345–1351.
   PubMed Web of Science ®Google Scholar
• MACRAE IM, ROBINSON MJ, MCAULEY MA, REID JL, MCCULLOCH J: Effects of intracisternal endothelin-1 injection on blood flow to the lower brain stem. Eur. J. Pharmacol. (1991) 203:85–91.
   PubMed Web of Science ®Google Scholar
• ROUX S, LOFFLER BM, GRAY GA et al: The role of endo-thelin in experimental cerebral vasospasm. Neurosur-gery (1995) 37:78–85.
   PubMed Web of Science ®Google Scholar
• SHIGENO T, CLOZEL M, SAKAI S, SAITO A, GOTO K: The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vaso-spasm. Neurosurgery (1995) 37:87–90.
   PubMed Web of Science ®Google Scholar
• SUZUKI R, MASAOKA H, HIRATA Y et al.: The role of endothelin-1 in the origin of cerebral vasospasm in pa-tients with aneurysmal subarachnoid haemorrhage. J. Neurosurg. (1992) 77:96–100.
   PubMed Web of Science ®Google Scholar
• ZIV I, HEMINGER G, DJALDETTI R et al.: Increased plasma endothelin-1 in acute ischaemic stroke. Stroke (1992) 23:1014–1016.
   PubMed Web of Science ®Google Scholar
• BARONE FC, GLOBUS MY-T, PRICE WJ et al.: Endothelin levels increase in rat focal and global ischaemia. J. Cereb. Blood Flow Metab. (1994) 14:337–342.
   PubMed Web of Science ®Google Scholar
• FINLAY JM, WEIR BKA, KANAMARU K, ESPINOSA F: Arte-rial wall changes in cerebral vasospasm. Neurosurgery (1989) 25:736–746.
   PubMed Web of Science ®Google Scholar
• ZUCCARELLO M, SOATTIN GB, LEWIS Al et al.: Preven-tion of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin re-ceptor antagonists. J. Neurosurg. (1996) 84:503–507.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN M, SEIFERT V, LOFFLER BM, STOLKE D, STENZEL W: Prevention of cerebral vasospasm after ex-perimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist. Neurosurgery (1996) 38:115–120.
   PubMed Web of Science ®Google Scholar
• ZUCCARELLO M, KASSELL NF, SASAKI T et al: Barrier dis-ruption in the major cerebral arteries after experi-mental subarachnoid hemorrhage in spontaneously hypertensive and normotensive rats. Neurosurgery (1987) 21:515–522.
   PubMed Web of Science ®Google Scholar
• HINO A, WEIR BK, MACDONALD RL et al.: Prospective, randomized, double-blind trial of BQ-123 and bosen-tan for prevention of vasospasm following subarach-noid hemorrhage in monkeys. J. Neurosurg. (1995) 83:503–509.
   PubMed Web of Science ®Google Scholar
• MCKENZIE AL, HALL JJ, AIHARA N, FUKUDA K, NOBLE LJ: Immunolocalization of endothelin in the traumatized spinal cord: relationship to blood-spinal cord barrier breakdown. J. Neurotrauma (1995) 12:257–268.
   PubMed Web of Science ®Google Scholar
• PATEL TR, GALBRAITH S, MCAULEY MA, MCCULLOCH J: Endothelin-mediated vascular tone following focal cerebral ischaemia in the cat. J. Cereb. Blood Flow Metab. (1996) 16:679–687.
   PubMed Web of Science ®Google Scholar
• PATEL TR, MCAULEY MA, MCCULLOCH J: Effects on fe-line pial arterioles in situ of bosentan, a non-peptide endothelin receptor antagonist. Eur. J. Pharmacol. (1994) 260:65–71.
   PubMed Web of Science ®Google Scholar
• MCAULEY MA, BREU V, GRAHAM DI, MCCULLOCH J: The effects of bosentan on cerebral blood flow and histo-pathology following middle cerebral artery occlusion in the rat. Eur. J. Pharmacol. (1996) 307:171–181.
   PubMed Web of Science ®Google Scholar
• PATEL TR, MCCULLOCH J: Failure of an endothelin an-tagonist to modify hypoperfusion after transient global ischaemia in the rat. J. Cereb. Blood Flow Metab. (1996) 16:490–499.
   PubMed Web of Science ®Google Scholar
• YASUMA Y, MCCARRON RM, RUETZLER C, STRASSER A, SPATZ M: ETA receptor-mediated post-ischemic cere-bral hypoperfusion. In: Pharmacology of Cerebral Ischae-mia J Krieglstein (Ed.). (1996) :291–298.
   Google Scholar
• YAMASHITA M, KASSELL NF, SASAKI T et al.: Topographi-cal distribution of barrier function in cervico-cephalic arteries of dog. Stroke (1985) 16:875–879.
   PubMed Web of Science ®Google Scholar
• BRANDLI P, LOFFLER BM, BREU V et al.: Role of endothe-lin in mediating neurogenic plasma extravasation in rat dura mater. Pain (1996) 64:315–322.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ MA: The neurobiology of vascular head pain. Ann. Neurol. (1984) 16:157–168.
   PubMed Web of Science ®Google Scholar
• WU-WONG JR, CHIOU WJ, HOFFMAN DJ et al.: Endothe-lins and endothelin receptor antagonists: binding to plasma proteins. Life Sci. (1996) 58:1839–1847.
   PubMed Web of Science ®Google Scholar
• KIOWSKI W, SUTSCH G, HUNZIKER P et al: Evidence for endothelin- 1-mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 346: 732–736.
   PubMed Web of Science ®Google Scholar
• StITSCH G, BERTEL 0, KIOWSKI W: Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc. Drugs Ther. (1997) 10:717–725.
   PubMed Web of Science ®Google Scholar
• StITSCH G, CHRISTENS, YAN X-W et al.: Clinical and he-modynamic effects of an orally active endothelin-1 re-ceptor antagonist in patients with refractory chronic heart failure. Circulation (1997) 96:193.
   Web of Science ®Google Scholar
• WALLNOFER A, GROSSET D, OHMAN J et al.: Effects of the endothelin antagonist bosentan in patients with elevated Doppler velocities after aneurysmal SAH. Pro-ceedings of the 6th International Conference on Cerebral Vasospasm (1997)
   Google Scholar
• KRUM H, VISKOPER RJ, LACOURCIERE Y, BUDDE M, CHARLON V: The effect of an endothelin-receptor an-tagonist, bosentan, on blood pressure in patients with essential hypertension. New EngL J. Med. (1998) 338:784–790.
   PubMed Web of Science ®Google Scholar
• WENZEL RR, FLEISCH M, SHAW S et al.: Hemodynamic and coronary effects of the endothelin antagonist bo-sentan in patients with coronary artery disease. Circu-lation (1997) (Submitted).
   Google Scholar
• MAY A, GIJSMAN HJ, WALLNOFER A et al.: Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain (1996) 67:375–378.
   PubMed Web of Science ®Google Scholar